Statistical analyses showed no significant association between LLT1 or CD161 expression in RS cells and HL subtype, stage or EBV status.<h4>Discussion</h4>These findings provide the first characterization of LLT1 and CD161 expression in RS cells and suggest their potential use as a target in immunotherapy approaches in HL. The gene discussed is CLEC2D; the disease is Hodgkins lymphoma.